동아제약 3분기 매출 4310억 달성
Predicted impact: Low
Q3 sales of ₩431B and operating profit of ₩35.1B; small versus the ₩1.5T revenue base and already reported.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.